Skip to content

JOHNSON & JOHNSON

Follow

13F filer, CIK 200406, NEW BRUNSWICK, NJ

JOHNSON & JOHNSON reported $761,691,304 across 15 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-10-26. Its ten largest share positions make up 98.81% of the portfolio.

Accepted , ingested 13F-HR 0000904454-26-000541

Period
2026-09-30
Reported value
$762M
Holdings
15
Top 10 weight
98.81%
New
0
Sold out
0

Stakes and trades reported after 2026-09-30

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • TRXB TREX BIO INC: 13G 1,475,302 shares, 5.3% of the class, 13G filed 2026-10-15, 0000904454-26-000517Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CBRSadded+75,063$13.3M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

None.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0000904454-26-000541, largest first. % of portfolio is the value over $761,691,304, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PTGXPROTAGONIST THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,449,183 shares; 2025Q1: 2,449,183 shares; 2025Q2: 2,449,183 shares; 2025Q3: 2,449,183 shares; 2025Q4: 2,449,183 shares; 2026Q1: 2,449,183 shares; 2026Q2: 2,449,183 shares; 2026Q3: 2,449,183 shares 2,449,183$345M45.3%0Timeline
NBTXNANOBIOTIXQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 5,623,816 shares; 2025Q1: 5,623,816 shares; 2025Q2: 5,623,816 shares; 2025Q3: 5,623,816 shares; 2025Q4: 5,623,816 shares; 2026Q1: 5,623,816 shares; 2026Q2: 5,623,816 shares; 2026Q3: 5,623,816 shares 5,623,816$175M23.01%0Timeline
MGTXMEIRAGTX HLDGS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 6,641,064 shares; 2025Q1: 6,641,064 shares; 2025Q2: 6,641,064 shares; 2025Q3: 6,641,064 shares; 2025Q4: 6,641,064 shares; 2026Q1: 6,641,064 shares; 2026Q2: 6,641,064 shares; 2026Q3: 6,641,064 shares 6,641,064$73.1M9.59%0Timeline
RAPPRAPPORT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,498,051 shares; 2025Q1: 2,498,051 shares; 2025Q2: 2,498,051 shares; 2025Q3: 1,784,517 shares; 2025Q4: 1,784,517 shares; 2026Q1: 1,784,517 shares; 2026Q2: 1,784,517 shares; 2026Q3: 1,784,517 shares 1,784,517$60M7.87%0Timeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,979,173 shares; 2025Q1: 1,979,173 shares; 2025Q2: 1,979,173 shares; 2025Q3: 1,979,173 shares; 2025Q4: 1,979,173 shares; 2026Q1: 1,979,173 shares; 2026Q2: 1,979,173 shares; 2026Q3: 1,979,173 shares 1,979,173$26.6M3.49%02026-11-03, 13G/A: 1,979,173 shares, 5.6% of the class, 13G/A filed 2026-11-06 Timeline
CBRSCEREBRAS SYSTEMS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 53,586 shares; 2026Q3: 128,649 shares 128,649$22.9M3%+75,063Timeline
XNCRXENCOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 748,062 shares; 2025Q1: 748,062 shares; 2025Q2: 748,062 shares; 2025Q3: 748,062 shares; 2025Q4: 748,062 shares; 2026Q1: 748,062 shares; 2026Q2: 748,062 shares; 2026Q3: 748,062 shares 748,062$18.7M2.45%0Timeline
LEGNLEGEND BIOTECH CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 814,586 shares; 2025Q1: 814,586 shares; 2025Q2: 814,586 shares; 2025Q3: 814,586 shares; 2025Q4: 814,586 shares; 2026Q1: 814,586 shares; 2026Q2: 814,586 shares; 2026Q3: 814,586 shares 814,586$16.2M2.13%0Timeline
FATEFATE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,379,064 shares; 2025Q1: 3,379,064 shares; 2025Q2: 3,379,064 shares; 2025Q3: 3,379,064 shares; 2025Q4: 3,379,064 shares; 2026Q1: 3,379,064 shares; 2026Q2: 3,379,064 shares; 2026Q3: 3,379,064 shares 3,379,064$8.01M1.05%0Timeline
CVRXCVRX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 4,103,430 shares; 2025Q1: 4,103,430 shares; 2025Q2: 4,103,430 shares; 2025Q3: 4,103,430 shares; 2025Q4: 4,024,861 shares; 2026Q1: 4,024,861 shares; 2026Q2: 4,024,861 shares; 2026Q3: 4,024,861 shares 4,024,861$7.04M0.92%0Timeline
PRCTPROCEPT BIOROBOTICS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 357,939 shares; 2025Q1: 357,939 shares; 2025Q2: 357,939 shares; 2025Q3: 357,939 shares; 2025Q4: 357,939 shares; 2026Q1: 357,939 shares; 2026Q2: 357,939 shares; 2026Q3: 357,939 shares 357,939$6.52M0.86%0Timeline
NMRANEUMORA THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,849,445 shares; 2025Q1: 1,849,445 shares; 2025Q2: 1,849,445 shares; 2025Q3: 1,849,445 shares; 2025Q4: 1,849,445 shares; 2026Q1: 1,849,445 shares; 2026Q2: 1,849,445 shares; 2026Q3: 1,849,445 shares 1,849,445$1.1M0.14%0Timeline
VORVOR BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 53,732 shares; 2026Q1: 53,732 shares; 2026Q2: 53,732 shares; 2026Q3: 53,732 shares 53,732$1.03M0.13%0Timeline
LABSTANDARD BIOTOOLS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 311,967 shares; 2025Q1: 311,967 shares; 2025Q2: 311,967 shares; 2025Q3: 311,967 shares; 2025Q4: 311,967 shares; 2026Q1: 311,967 shares; 2026Q2: 311,967 shares; 2026Q3: 311,967 shares 311,967$231K0.03%0Timeline
ACETADICET BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 22,779 shares; 2026Q1: 22,779 shares; 2026Q2: 22,779 shares; 2026Q3: 22,779 shares 22,779$163K0.02%0Timeline

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000904454-26-000541 base2026-10-26

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0000904454-26-000541 Quarter ended 2026-09-302026-10-26
13F-HR 0000904454-26-000435 Quarter ended 2026-06-302026-08-06acceptance time not in the bulk data set
13F-HR 0000904454-26-000280 Quarter ended 2026-03-312026-05-13acceptance time not in the bulk data set
13F-HR/A 0000904454-26-000192 Quarter ended 2025-12-312026-03-18acceptance time not in the bulk data set
13F-HR/A 0000904454-26-000190 Quarter ended 2025-09-302026-03-18acceptance time not in the bulk data set
13F-HR 0000904454-26-000111 Quarter ended 2025-12-312026-02-13acceptance time not in the bulk data set
13F-HR 0000904454-25-000587 Quarter ended 2025-09-302025-11-13acceptance time not in the bulk data set
13F-HR 0000904454-25-000367 Quarter ended 2025-06-302025-07-22acceptance time not in the bulk data set
13F-HR 0000904454-25-000238 Quarter ended 2025-03-312025-05-07acceptance time not in the bulk data set
13F-HR 0000904454-25-000124 Quarter ended 2024-12-312025-02-13acceptance time not in the bulk data set
13F-HR 0000904454-24-000604 Quarter ended 2024-09-302024-11-13acceptance time not in the bulk data set
13F-HR 0000904454-24-000451 Quarter ended 2024-06-302024-08-09acceptance time not in the bulk data set
13F-HR 0000904454-24-000285 Quarter ended 2024-03-312024-05-10acceptance time not in the bulk data set
13F-HR 0000904454-24-000151 Quarter ended 2023-12-312024-02-14acceptance time not in the bulk data set
13F-HR 0000904454-23-000600 Quarter ended 2023-09-302023-11-09acceptance time not in the bulk data set
13F-HR 0000904454-23-000459 Quarter ended 2023-06-302023-08-02acceptance time not in the bulk data set
13F-HR 0000904454-23-000307 Quarter ended 2023-03-312023-05-11acceptance time not in the bulk data set
13F-HR 0001567619-23-002139 Quarter ended 2022-12-312023-02-09acceptance time not in the bulk data set
13F-HR 0001567619-22-019556 Quarter ended 2022-09-302022-11-10acceptance time not in the bulk data set
13F-HR 0001567619-22-015421 Quarter ended 2022-06-302022-08-10acceptance time not in the bulk data set
13F-HR 0001567619-22-009807 Quarter ended 2022-03-312022-05-09acceptance time not in the bulk data set
13F-HR 0001567619-22-004279 Quarter ended 2021-12-312022-02-14acceptance time not in the bulk data set
13F-HR/A 0001567619-21-020557 Quarter ended 2021-09-302021-11-16acceptance time not in the bulk data set
13F-HR 0001567619-21-020090 Quarter ended 2021-09-302021-11-12acceptance time not in the bulk data set
13F-NT 0001567619-21-014325 Quarter ended 2021-06-302021-08-03acceptance time not in the bulk data set
13F-NT 0001567619-21-009229 Quarter ended 2021-03-312021-05-07acceptance time not in the bulk data set
13F-NT 0001567619-21-002492 Quarter ended 2020-12-312021-02-09acceptance time not in the bulk data set
13F-NT 0001567619-20-018620 Quarter ended 2020-09-302020-11-03acceptance time not in the bulk data set
13F-NT 0001567619-20-014845 Quarter ended 2020-06-302020-08-12acceptance time not in the bulk data set
13F-NT 0001567619-20-009798 Quarter ended 2020-03-312020-05-13acceptance time not in the bulk data set
13F-NT 0001567619-20-003767 Quarter ended 2019-12-312020-02-14acceptance time not in the bulk data set